Page 182 - Mployee Wellness Programs News Today

Panelists at a recent healthcare conference expressed optimism about the automation technology that health plans, pharmacy benefit managers and providers can adopt to facilitate real-time data sharing. They said that such technology has potential to improve medication adherence, reduce costs and save time for both providers and payers.

Making operational changes to ease the unpredictable nature of respiratory season is the right thing to do for staff, for patients, and for the business. Digital solutions and better processes allow staff to work smarter and faster and prepare them for high-volume days ahead of time so they feel in control.

The increased demand for stimulant medications such as Adderall for ADHD is not the result of abuse or misdiagnosis but is caused by a previously unmet need for treatment of ADHD, which telepsychiatry finally satisfied.

Chiesi drug Lamzede is an engineered version of an enzyme that’s lacking in patients with the rare disease alpha-mannosidosis. FDA approval of the Chiesi drug comes about five years after European regulators authorized the product.

BlueCross BlueShield of Tennessee's health equity report analyzed disparities in behavioral health, cancer, child and adolescent care, chronic condition management, Covid-19 and maternal health.

Grifols said the layoffs sparked by its restructuring represent just 8% of its workforce. But the cuts will happen mainly in the Barcelona-based company’s U.S. plasma operations, source of most of the plasma that is the basis for its biologic medicines.

Pharma players, now more than ever, need a new and powerful tool to differentiate their products. We believe the next decade of transformation is digital.

Elation Health announced its acquisition of medical billing company Lightning MD — a deal the company made to help it become an all-in-one technology platform for primary care providers. Lighting MD stood out from other medical billing startups because of its ease of use, Elation CEO Kyna Fong said.

A webinar sponsored by BD scheduled for March 7 will explore how diagnostics companies are working with healthcare organizations to guard against the perfect storm of Covid-19, RSV and influenza. Register today!

While Talaris Therapeutics is ending two clinical tests of its cell therapy in kidney transplant patients, a third study in the autoimmune condition scleroderma is continuing. Meanwhile, the biotech’s restructuring plan is pursuing “strategic alternatives” that could include a merger or sale.